OneSkin

Carolina Reis Oliveira's first big professional swing wasn't a moisturizer at all. Before this venture, she ran a biotech startup in Brazil building lab-grown skin models to replace animal testing for cosmetics safety, and it was that work, staring at engineered tissue all day, that pushed her toward a stranger question: could the skin itself be reprogrammed to behave younger? She and her future colleague had trained side by side in the same lab years earlier, both immersed in stem-cell biology and tissue engineering, and they relocated to the Bay Area chasing that idea rather than a product.

The screening process behind the OS-01 molecule is the part worth understanding. The team didn't dream up a peptide and reverse-engineer a marketing story; they ran candidate molecules against their own engineered skin tissue, measuring whether each one actually reduced markers of senescent, inflammation-spewing cells. The winner was selected because it scored best on those assays, then formulated into a topical only afterward. That order of operations, biology first and bottle second, is the genuinely unusual thing here.

The product line grew outward from a single hero molecule into a deliberately narrow system: a face supplement, then body, eye, a cleanser meant to prep skin, and an SPF that carries the same peptide. Rather than chase trends, each release essentially asks where else the OS-01 chemistry might do useful work. The brand has cultivated a following in longevity and biohacking circles, where the language of "hallmarks of aging" already resonates, and it has leaned into academic-style publishing as both ethos and differentiator.

The approach has limits worth naming. A platform built on one proprietary molecule lives or dies by how that molecule holds up under independent scrutiny over time, and the longevity framing invites bigger expectations than any daily topical can meet. But as a case study in a research-first beauty company, it remains a rare one.

Sources:[1][2][3]